Chinyu Su

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, UPenn Medical Center Presbyterian, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
    Gastroenterology 126:1257-69. 2004
  2. ncbi A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania and University of Pennsylvania Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Gastroenterology 132:516-26. 2007
  3. ncbi Outcomes of placebo therapy in inflammatory bowel disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, PA 19104, USA
    Inflamm Bowel Dis 12:328-33. 2006
  4. ncbi Recent developments in inflammatory bowel disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Third Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
    Med Clin North Am 86:1497-523. 2002
  5. ncbi Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
    Gastroenterol Clin North Am 33:209-34, viii. 2004
  6. ncbi The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease
    Michael Pazianas
    Department of Medicine, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA
    Ann N Y Acad Sci 1068:543-56. 2006
  7. ncbi Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
    Chinyu Su
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
    Am J Gastroenterol 97:2577-84. 2002
  8. ncbi Trends in hospitalization rates for inflammatory bowel disease in the United States
    Meenakshi Bewtra
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 5:597-601. 2007
  9. ncbi Are there predictors of Remicade treatment success or failure?
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Adv Drug Deliv Rev 57:237-45. 2005
  10. ncbi Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0956, USA
    N Engl J Med 367:616-24. 2012

Detail Information

Publications11

  1. ncbi A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, UPenn Medical Center Presbyterian, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
    Gastroenterology 126:1257-69. 2004
    ..The aims of this study were to estimate rates of remission and response in patients with active CD receiving placebo and to identify factors influencing these rates...
  2. ncbi A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania and University of Pennsylvania Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Gastroenterology 132:516-26. 2007
    ..The aims of this study were to estimate the placebo rates of remission and response in placebo-controlled, randomized clinical trials for active UC and to identify factors influencing these rates...
  3. ncbi Outcomes of placebo therapy in inflammatory bowel disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, PA 19104, USA
    Inflamm Bowel Dis 12:328-33. 2006
    ..This review presents our current knowledge of placebo therapy in IBD. Specifically, the existing literature on the outcomes and predictors of outcomes in patients receiving placebo therapy in clinical trials of IBD is reviewed...
  4. ncbi Recent developments in inflammatory bowel disease
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Third Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
    Med Clin North Am 86:1497-523. 2002
    ....
  5. ncbi Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
    Gastroenterol Clin North Am 33:209-34, viii. 2004
    ..Emerging literature on the potential application of pharmacogenetic testing and metabolite monitoring are also discussed...
  6. ncbi The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease
    Michael Pazianas
    Department of Medicine, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA
    Ann N Y Acad Sci 1068:543-56. 2006
    ....
  7. ncbi Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
    Chinyu Su
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
    Am J Gastroenterol 97:2577-84. 2002
    ..Individuals who are refractory to corticosteroids, however, may be unlikely to respond to infliximab. A randomized controlled trial is necessary to further investigate the efficacy of infliximab in patients with UC...
  8. ncbi Trends in hospitalization rates for inflammatory bowel disease in the United States
    Meenakshi Bewtra
    Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Gastroenterol Hepatol 5:597-601. 2007
    ..This study examined trends in hospitalization and surgery rates for inflammatory bowel disease (IBD) in the United States over a 14-year period...
  9. ncbi Are there predictors of Remicade treatment success or failure?
    Chinyu Su
    Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Adv Drug Deliv Rev 57:237-45. 2005
    ..Data from the literature in these areas are reviewed in this article, pointing to the need for additional research in this topic...
  10. ncbi Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0956, USA
    N Engl J Med 367:616-24. 2012
    ..These cytokines are integral to lymphocyte activation, function, and proliferation...
  11. ncbi O brother, where art thou? The case for siblings, environment, and inflammatory bowel disease
    Chinyu Su
    Division of Gastroenterology, University of Pennsylvania School of Medicine, University of Pennsylvania Medical Center Presbyterian, Philadelphia, USA
    Inflamm Bowel Dis 9:211-2. 2003